サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1457355

爪真菌症治療の世界市場：製品タイプ別、エンドユーザー別、地域別 - 世界産業分析、規模、シェア、成長、動向、予測（2023～2030年）

Onychomycosis Treatment Market by Product Type, End-Users, and Geography (North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa): Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2030
出版日: | 発行: Persistence Market Research | ページ情報: 英文 234 Pages | 納期: 2～5営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
爪真菌症治療の世界市場：製品タイプ別、エンドユーザー別、地域別 - 世界産業分析、規模、シェア、成長、動向、予測（2023～2030年）
出版日: 2024年02月16日
発行: Persistence Market Research
ページ情報: 英文 234 Pages
納期: 2～5営業日
  • 全表示
  • 概要
  • 目次
概要

世界の爪真菌症治療の市場規模は、2023年に510億米ドルに達し、CAGR 7.6%で拡大し、2030年末には851億米ドルに達すると予測されています。

主要洞察

爪真菌症治療市場規模（2023E）：510億米ドル

予測市場金額（2030F）：851億米ドル

世界の市場成長率（CAGR 2023～2030年）：7.6%

過去の市場成長率（CAGR 2018～2022年）：4.9%

爪真菌症治療市場 - 調査範囲

爪真菌症治療市場レポートは、市場促進要因・抑制要因・機会・課題を含む市場力学の包括的分析を提供します。爪の変色、肥厚、変形を特徴とする爪真菌症は、主に皮膚糸状菌によって引き起こされ、医療提供者に診断と治療の課題を提示します。本レポートでは、爪真菌症治療のニュアンスを掘り下げ、市場成長に影響を与える要因、競合情勢、抗真菌療法の技術革新を促進する新たな動向を調査しています。

爪真菌症治療市場の市場促進要因：

人口動態の高齢化、糖尿病、免疫抑制、足の不衛生などの要因に起因する爪真菌症の有病率の増加は、爪真菌症治療市場の主要促進要因です。高齢者や基礎疾患を持つ患者は、免疫機能の低下、末梢循環の低下、爪の構造的変化により、特に真菌性爪感染症にかかりやすく、タイムリーな診断と治療介入が必要となります。

さらに、痛み、不快感、恥ずかしさ、生活の質の低下など、爪真菌症の臨床的影響や心理社会的影響に対する意識の高まりが、効果的な治療オプションに対する患者や医師の需要を促進しています。爪真菌症治療は、真菌病原体を根絶し、爪の健康を回復させ、疾患の再発を予防し、罹患者に症状の緩和と美容的改善を提供することを目的としています。

新しい外用剤、内服薬、爪の剥離やレーザー治療のための医療機器の開発など、抗真菌療法における技術の進歩は、治療結果、患者のコンプライアンス、治療効果を向上させています。ヘルスケアプロバイダーや患者の臨床的ニーズや嗜好の変化に対応するため、ドラッグデリバリーシステムの革新、抗真菌力の強化、治療レジメンの最適化のための研究開発に各メーカーが投資しています。

市場抑制要因

有望な市場展望にもかかわらず、爪真菌症治療市場は、治療抵抗性、安全性への懸念、規制上の障壁に関する課題に直面しています。真菌性爪感染症は、爪の成長速度が遅いこと、爪下残屑が存在すること、抗真菌剤耐性が発達していることなどから治療が困難であり、長期的かつ多角的な治療アプローチが必要となります。

さらに、経口アゾール系抗真菌薬やアリルアミン系抗真菌薬などの全身性抗真菌薬は、副作用、薬物相互作用、肝毒性を伴う可能性があり、高齢者や肝障害者など特定の患者集団における有用性が制限されます。安全性への配慮、薬剤の忍容性、治療のアドヒアランスは、爪水虫管理における治療法の選択と患者の転帰に影響を与える重要な要素です。

市場機会

課題の中には、爪真菌症治療市場における技術革新、コラボレーション、市場拡大の機会が潜んでいます。医療真菌学、皮膚薬理学、抗真菌薬創製の進歩を活用することで、有効性、安全性、患者の利便性を向上させた次世代治療薬の開発が促進されます。

さらに、製薬企業、学術機関、研究機関の協力関係を促進することで、新規抗真菌薬や治療法の医薬品開発構想、前臨床試験、臨床試験を加速することができます。ゲノミクス、プロテオミクス、ハイスループットスクリーニング技術を活用することで、研究者は新たな創薬ターゲットを同定し、既存の薬剤を再利用し、爪真菌症に対する治療レジメンを最適化することができます。

爪真菌症の予防、診断、治療に関する認識を高めることを目的とした教育的イニシアチブは、ヘルスケアプロバイダーと患者がエビデンスに基づいた診療を採用し、タイムリーな医療介入を求める力を与えることができます。患者教育資料、臨床診療ガイドライン、継続的な医学教育プログラムは、爪真菌症管理における診断精度、治療アドヒアランス、長期的な臨床転帰を改善する上で重要な役割を果たします。

レポートで回答した主な質問

  • 2030年における爪真菌症治療市場の予測CAGRは？
  • 2023年末時点での爪真菌症治療薬の世界市場規模は？
  • 2023年の爪真菌症治療薬市場を独占した地域はどこか？
  • 爪真菌症治療の世界市場における主要プレイヤーは？
  • 市場統合の最大の機会を握る爪真菌症治療セグメントは？

目次

第1章 エグゼクティブサマリー

第2章 市場概要

  • 市場の範囲と定義
  • 市場力学
    • 促進要因
    • 抑制要因
    • 機会
    • 課題
    • 主要な動向
  • 治療タイプのライフサイクル分析
  • 爪真菌症治療市場：バリューチェーン
    • 原材料サプライヤー一覧
    • メーカー一覧
    • 販売代理店一覧
    • アプリケーション一覧
    • 収益性分析
  • ポーターファイブフォースの分析
  • 地政学的緊張：市場への影響
  • マクロ経済的要因
    • 世界のセクター別展望
    • 世界のGDP成長率の展望
    • 世界の親市場概要
  • 予測要因- 関連性と影響
  • 規制とテクノロジーの情勢

第3章 世界の爪真菌症治療市場の展望：過去（2018～2022年）と予測（2023～2030年）

  • 主なハイライト
    • 市場数量（単位）予測
    • 市場規模と前年比成長率
    • 絶対的金額のチャンス
  • 市場規模（100万米ドル）分析と予測
    • 過去の市場規模分析、2013～2016年
    • 現在の市場規模予測、2018～2026年
  • 世界の爪真菌症治療市場の展望：治療タイプ
    • イントロダクション/主な調査結果
    • 過去の市場規模（100万米ドル）および数量（単位）分析：治療タイプ別、2018～2022年
    • 現在の市場規模（100万米ドル）と数量（単位）予測：治療タイプ別、2023～2030年
    • 市場魅力度分析：治療タイプ
  • 世界の爪真菌症治療市場の展望：適応疾患
    • イントロダクション/主な調査結果
    • 過去の市場規模（100万米ドル）および数量（単位）分析：適応疾患別、2018～2022年
    • 現在の市場規模（100万米ドル）と数量（単位）予測：適応疾患別、2023～2030年
    • 市場魅力度分析：適応疾患
  • 世界の爪真菌症治療市場の展望：年齢層
    • イントロダクション/主な調査結果
    • 過去の市場規模（100万米ドル）および数量（単位）分析：年齢層別、2018～2022年
    • 現在の市場規模（100万米ドル）と数量（単位）予測：年齢層別、2023～2030年
    • 市場魅力度分析：年齢層
  • 世界の爪真菌症治療市場の展望：流通チャネル
    • イントロダクション/主な調査結果
    • 過去の市場規模（100万米ドル）および数量（単位）分析：流通チャネル別、2018～2022年
    • 現在の市場規模（100万米ドル）と数量（単位）予測：流通チャネル別、2023～2030年
    • 市場魅力度分析：流通チャネル

第4章 世界の爪真菌症治療市場の展望：地域

  • 主なハイライト
  • 過去の市場規模（100万米ドル）および数量（単位）分析：地域別、2018～2022年
  • 現在の市場規模（100万米ドル）と数量（単位）予測：地域別、2023～2030年
    • 北米
    • 欧州
    • 東アジア
    • 南アジアとオセアニア
    • ラテンアメリカ
    • 中東・アフリカ
  • 市場魅力度分析：地域

第5章 北米の爪真菌症治療市場の展望：過去（2018～2022年）と予測（2023～2030年）

第6章 欧州の爪真菌症治療市場の展望：過去（2018～2022年）と予測（2023～2030年）

第7章 東アジアの爪真菌症治療市場の展望：過去（2018～2022年）と予測（2023～2030年）

第8章 南アジア・オセアニアの爪真菌症治療市場の展望：過去（2018～2022年）と予測（2023～2030年）

第9章 ラテンアメリカの爪真菌症治療市場の展望：過去（2018～2022年）と予測（2023～2030年）

第10章 中東・アフリカの爪真菌症治療市場の展望：過去（2018～2022年）と予測（2023～2030年）

第11章 競合情勢

  • 市場シェア分析、2022年
  • 市場構造
  • 企業プロファイル
    • Teva Pharmaceutical Industries Ltd.
    • Sanofi SA
    • Medimetriks Pharmaceuticals, Inc.
    • Galderma
    • Johnson &Johnson
    • Novartis AG
    • Moberg Pharma AB
    • Cardinal Health, Inc.
    • Pfizer Inc.
    • Almirall, SA
    • Bayer AG
    • Viatris Inc.
    • GlaxoSmithKline plc
    • Cipla Ltd.
    • Dr. Reddy's Laboratories Ltd

第12章 付録

目次
Product Code: PMRREP34004

Persistence Market Research presents a comprehensive report on the global Onychomycosis Treatment Market, highlighting its substantial growth potential driven by the increasing prevalence of fungal nail infections and the rising demand for effective treatment options. Onychomycosis, a common fungal infection of the nails, poses significant clinical and aesthetic concerns, leading to a growing burden on healthcare systems and impacting patients' quality of life. The report emphasizes the critical need for innovative and efficacious treatments to address this prevalent dermatological condition effectively.

The global onychomycosis treatment market is forecast to expand at a CAGR of 7.6% and thereby increase from a value of US$51 Bn in 2023, to US$85.1 Bn by the end of 2030.

Key Insights

Onychomycosis Treatment Market Size (2023E): US$51 billion

Projected Market Value (2030F): US$85.1 billion

Global Market Growth Rate (CAGR 2023 to 2030): 7.6%

Historical Market Growth Rate (CAGR 2018 to 2022): 4.9%

Onychomycosis Treatment Market - Report Scope

The Onychomycosis Treatment Market report provides a comprehensive analysis of market dynamics, including drivers, restraints, opportunities, and challenges shaping the industry landscape. Onychomycosis, characterized by nail discoloration, thickening, and deformity, is predominantly caused by dermatophyte fungi, presenting diagnostic and therapeutic challenges for healthcare providers. The report delves into the nuances of onychomycosis treatment, examining factors influencing market growth, competitive landscape, and emerging trends driving innovation in antifungal therapies.

Market Growth Drivers for Onychomycosis Treatment Market:

The increasing prevalence of onychomycosis, attributed to factors such as aging demographics, diabetes mellitus, immunosuppression, and poor foot hygiene, is a primary driver for the onychomycosis treatment market. Elderly individuals and patients with underlying medical conditions are particularly susceptible to fungal nail infections due to compromised immune function, reduced peripheral circulation, and structural nail changes, necessitating timely diagnosis and treatment interventions.

Furthermore, the growing awareness about the clinical consequences and psychosocial impact of onychomycosis, including pain, discomfort, embarrassment, and impaired quality of life, is driving patient and physician demand for effective treatment options. Onychomycosis treatment aims to eradicate fungal pathogens, restore nail health, and prevent disease recurrence, offering symptomatic relief and cosmetic improvement for affected individuals.

Technological advancements in antifungal therapies, including the development of novel topical formulations, oral medications, and medical devices for nail debridement and laser therapy, are enhancing treatment outcomes, patient compliance, and therapeutic efficacy. Manufacturers are investing in research and development to innovate drug delivery systems, enhance antifungal potency, and optimize treatment regimens, aiming to address the evolving clinical needs and preferences of healthcare providers and patients.

Market Restraints

Despite the promising market outlook, the onychomycosis treatment market faces challenges related to treatment resistance, safety concerns, and regulatory barriers. Fungal nail infections can be challenging to treat due to the slow growth rate of nails, the presence of subungual debris, and the development of antifungal resistance, necessitating prolonged and multifaceted treatment approaches.

Moreover, systemic antifungal medications, such as oral azoles and allylamines, may be associated with adverse effects, drug interactions, and hepatotoxicity, limiting their utility in certain patient populations, including elderly individuals and those with liver impairment. Safety considerations, drug tolerability, and treatment adherence are crucial factors influencing treatment selection and patient outcomes in onychomycosis management.

Market Opportunities

Amidst the challenges lie opportunities for innovation, collaboration, and market expansion within the onychomycosis treatment market. Leveraging advancements in medical mycology, dermatopharmacology, and antifungal drug discovery can facilitate the development of next-generation therapies with improved efficacy, safety, and patient convenience.

Furthermore, fostering collaborations between pharmaceutical companies, academic institutions, and research organizations can accelerate drug development initiatives, preclinical studies, and clinical trials for novel antifungal agents and treatment modalities. By leveraging genomics, proteomics, and high-throughput screening technologies, researchers can identify new drug targets, repurpose existing medications, and optimize therapeutic regimens for onychomycosis.

Educational initiatives aimed at raising awareness about onychomycosis prevention, diagnosis, and treatment can empower healthcare providers and patients to adopt evidence-based practices and seek timely medical intervention. Patient education materials, clinical practice guidelines, and continuing medical education programs play a crucial role in improving diagnostic accuracy, treatment adherence, and long-term clinical outcomes in onychomycosis management.

Key Questions Answered in Report::

  • What is the Forecast CAGR of the Onychomycosis Treatment Market in 2030?
  • What is the Global Market Size of Onychomycosis Treatment as of the End of 2023?
  • Which Region Dominated the Onychomycosis Treatment Market in 2023?
  • Who are the Key Players in the Global Onychomycosis Treatment Market?
  • Which Onychomycosis Treatment Segments Hold the Largest Opportunities for Market Integration?

Competitive Intelligence and Business Strategy

In navigating the competitive landscape, companies in the Onychomycosis Treatment Market must leverage competitive intelligence and strategic business initiatives to differentiate themselves and capitalize on emerging opportunities. Understanding market dynamics, customer preferences, and competitor strategies is essential for informed decision-making and market positioning.

Furthermore, investing in research and development, clinical trials, and regulatory compliance can help companies bring innovative therapies to market, gain regulatory approval, and expand market share. By focusing on patient-centric approaches, physician education, and market access strategies, companies can enhance product adoption, drive revenue growth, and improve patient outcomes in the dynamic Onychomycosis Treatment Market.

Key Companies Profiled

  • Teva Pharmaceutical Industries Ltd.
  • Sanofi S.A.
  • Medimetriks Pharmaceuticals, Inc.
  • Galderma
  • Johnson & Johnson
  • Novartis AG
  • Moberg Pharma AB
  • Cardinal Health, Inc.
  • Pfizer Inc.
  • Almirall, S.A.
  • Bayer AG
  • Viatris Inc.
  • GlaxoSmithKline plc
  • Cipla Ltd.
  • Dr. Reddy's Laboratories Ltd

Onychomycosis Treatment Market Research Segmentation

Market segmentation based on drug class, route of administration, distribution channel, and region provides valuable insights into key market segments and regional dynamics, enabling companies to tailor their offerings to specific customer needs and preferences. By understanding the unique requirements of different patient populations and geographic markets, companies can develop targeted strategies to address market demands effectively, thereby gaining a competitive edge and driving growth in the Onychomycosis Treatment Market.

Onychomycosis Treatment Market Research Segmentation

By Treatment Type:

  • Drugs
  • Oral
  • Rx
  • OTC
  • Topical
  • Rx
  • OTC
  • Lasers
  • C02 Ablative Lasers
  • Nd: YAG Lasers
  • Dual-wavelength near-infrared Lasers
  • Photodynamic Therapy

By Disease Indication:

  • Distal Subungual Onychomycosis
  • White Superficial Onychomycosis
  • Proximal Subungual Onychomycosis
  • Candidal Onychomycosis
  • Total Dystrophic Onychomycosis

By Age Group:

  • 0 to 18 Years
  • 18 to 39 Years
  • 40 to 64 Years
  • 65 Years & Above

By Distribution Channel:

  • Institutional Sales
  • Hospitals
  • Dermatology Clinics
  • Retail Sales
  • Retail Pharmacies
  • Drug Stores
  • Mail Order Pharmacies & Online Sales

By Region:

  • North America
  • Europe
  • East Asia
  • South Asia & Oceania
  • Latin America
  • Middle East & Africa

Table of Contents

1. Executive Summary

  • 1.1. Global Onychomycosis Treatment Market Snapshot, 2023 and 2030
  • 1.2. Market Opportunity Assessment, 2023 - 2030, US$ Mn
  • 1.3. Key Market Trends
  • 1.4. Future Market Projections
  • 1.5. Premium Market Insights
  • 1.6. Industry Developments and Key Market Events
  • 1.7. PMR Analysis and Recommendations

2. Market Overview

  • 2.1. Market Scope and Definition
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Opportunity
    • 2.2.4. Challenges
    • 2.2.5. Key Trends
  • 2.3. Treatment Type Lifecycle Analysis
  • 2.4. Onychomycosis Treatment Market: Value Chain
    • 2.4.1. List of Raw Material Supplier
    • 2.4.2. List of Manufacturers
    • 2.4.3. List of Distributors
    • 2.4.4. List of Applications
    • 2.4.5. Profitability Analysis
  • 2.5. Porter Five Force's Analysis
  • 2.6. Geopolitical Tensions: Market Impact
  • 2.7. Macro-Economic Factors
    • 2.7.1. Global Sectorial Outlook
    • 2.7.2. Global GDP Growth Outlook
    • 2.7.3. Global Parent Market Overview
  • 2.8. Forecast Factors - Relevance and Impact
  • 2.9. Regulatory and Technology Landscape

3. Global Onychomycosis Treatment Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)

  • 3.1. Key Highlights
    • 3.1.1. Market Volume (Units) Projections
    • 3.1.2. Market Size and Y-o-Y Growth
    • 3.1.3. Absolute $ Opportunity
  • 3.2. Market Size (US$ Mn) Analysis and Forecast
    • 3.2.1. Historical Market Size Analysis, 2013-2016
    • 3.2.2. Current Market Size Forecast, 2018-2026
  • 3.3. Global Onychomycosis Treatment Market Outlook: Treatment Type
    • 3.3.1. Introduction / Key Findings
    • 3.3.2. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Treatment Type, 2018 - 2022
    • 3.3.3. Current Market Size (US$ Mn) and Volume (Units) Forecast By Treatment Type, 2023 - 2030
      • 3.3.3.1. Drugs
        • 3.3.3.1.1. Oral
        • 3.3.3.1.2. Rx
        • 3.3.3.1.3. OTC
        • 3.3.3.1.4. Topical
        • 3.3.3.1.5. Rx
        • 3.3.3.1.6. OTC
      • 3.3.3.2. Lasers
        • 3.3.3.2.1. C02 Ablative Lasers
        • 3.3.3.2.2. Nd: YAG Lasers
        • 3.3.3.2.3. Dual-wavelength near-infrared Lasers
      • 3.3.3.3. Photodynamic Therapy
  • 3.4. Market Attractiveness Analysis: Treatment Type
  • 3.5. Global Onychomycosis Treatment Market Outlook: Disease Indication
    • 3.5.1. Introduction / Key Findings
    • 3.5.2. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Disease Indication, 2018 - 2022
    • 3.5.3. Current Market Size (US$ Mn) and Volume (Units) Forecast By Disease Indication, 2023 - 2030
      • 3.5.3.1. Distal Subungual Onychomycosis
      • 3.5.3.2. White Superficial Onychomycosis
      • 3.5.3.3. Proximal Subungual Onychomycosis
      • 3.5.3.4. Candidal Onychomycosis
      • 3.5.3.5. Total Dystrophic Onychomycosis
  • 3.6. Market Attractiveness Analysis: Disease Indication
  • 3.7. Global Onychomycosis Treatment Market Outlook: Age Group
    • 3.7.1. Introduction / Key Findings
    • 3.7.2. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Age Group, 2018 - 2022
    • 3.7.3. Current Market Size (US$ Mn) and Volume (Units) Forecast By Age Group, 2023 - 2030
      • 3.7.3.1. 0 to 18 Years
      • 3.7.3.2. 18 to 39 Years
      • 3.7.3.3. 40 to 64 Years
      • 3.7.3.4. 65 Years & Above
  • 3.8. Market Attractiveness Analysis: Age Group
  • 3.9. Global Onychomycosis Treatment Market Outlook: Distribution Channel
    • 3.9.1. Introduction / Key Findings
    • 3.9.2. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Distribution Channel, 2018 - 2022
    • 3.9.3. Current Market Size (US$ Mn) and Volume (Units) Forecast By Distribution Channel, 2023 - 2030
      • 3.9.3.1. Institutional Sales
      • 3.9.3.2. Hospitals
      • 3.9.3.3. Dermatology Clinics
      • 3.9.3.4. Retail Sales
      • 3.9.3.5. Retail Pharmacies
      • 3.9.3.6. Drug Stores
      • 3.9.3.7. Mail Order Pharmacies & Online Sales
  • 3.10. Market Attractiveness Analysis: Distribution Channel

4. Global Onychomycosis Treatment Market Outlook: Region

  • 4.1. Key Highlights
  • 4.2. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Region, 2018 - 2022
  • 4.3. Current Market Size (US$ Mn) and Volume (Units) Forecast By Region, 2023 - 2030
    • 4.3.1. North America
    • 4.3.2. Europe
    • 4.3.3. East Asia
    • 4.3.4. South Asia and Oceania
    • 4.3.5. Latin America
    • 4.3.6. Middle East & Africa (MEA)
  • 4.4. Market Attractiveness Analysis: Region

5. North America Onychomycosis Treatment Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)

  • 5.1. Key Highlights
  • 5.2. Pricing Analysis
  • 5.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
    • 5.3.1. By Country
    • 5.3.2. By Treatment Type
    • 5.3.3. By Disease Indication
    • 5.3.4. By Age Group
    • 5.3.5. By Distribution Channel
  • 5.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
    • 5.4.1. U.S.
    • 5.4.2. Canada
  • 5.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Treatment Type, 2023 - 2030
    • 5.5.1. Drugs
      • 5.5.1.1. Oral
      • 5.5.1.2. Rx
      • 5.5.1.3. OTC
      • 5.5.1.4. Topical
      • 5.5.1.5. Rx
      • 5.5.1.6. OTC
    • 5.5.2. Lasers
      • 5.5.2.1. C02 Ablative Lasers
      • 5.5.2.2. Nd: YAG Lasers
      • 5.5.2.3. Dual-wavelength near-infrared Lasers
    • 5.5.3. Photodynamic Therapy
  • 5.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By Disease Indication, 2023 - 2030
    • 5.6.1. Distal Subungual Onychomycosis
    • 5.6.2. White Superficial Onychomycosis
    • 5.6.3. Proximal Subungual Onychomycosis
    • 5.6.4. Candidal Onychomycosis
    • 5.6.5. Total Dystrophic Onychomycosis
  • 5.7. Current Market Size (US$ Mn) and Volume (Units) Forecast By Age Group, 2023 - 2030
    • 5.7.1. 0 to 18 Years
    • 5.7.2. 18 to 39 Years
    • 5.7.3. 40 to 64 Years
    • 5.7.4. 65 Years & Above
  • 5.8. Current Market Size (US$ Mn) and Volume (Units) Forecast By Distribution Channel, 2023 - 2030
    • 5.8.1. Institutional Sales
    • 5.8.2. Hospitals
    • 5.8.3. Dermatology Clinics
    • 5.8.4. Retail Sales
    • 5.8.5. Retail Pharmacies
    • 5.8.6. Drug Stores
    • 5.8.7. Mail Order Pharmacies & Online Sales
  • 5.9. Market Attractiveness Analysis

6. Europe Onychomycosis Treatment Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)

  • 6.1. Key Highlights
  • 6.2. Pricing Analysis
  • 6.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
    • 6.3.1. By Country
    • 6.3.2. By Treatment Type
    • 6.3.3. By Disease Indication
    • 6.3.4. By Age Group
    • 6.3.5. By Distribution Channel
  • 6.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
    • 6.4.1. Germany
    • 6.4.2. France
    • 6.4.3. U.K.
    • 6.4.4. Italy
    • 6.4.5. Spain
    • 6.4.6. Russia
    • 6.4.7. Turkiye
    • 6.4.8. Rest of Europe
  • 6.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Treatment Type, 2023 - 2030
    • 6.5.1. Drugs
      • 6.5.1.1. Oral
      • 6.5.1.2. Rx
      • 6.5.1.3. OTC
      • 6.5.1.4. Topical
      • 6.5.1.5. Rx
      • 6.5.1.6. OTC
    • 6.5.2. Lasers
      • 6.5.2.1. C02 Ablative Lasers
      • 6.5.2.2. Nd: YAG Lasers
      • 6.5.2.3. Dual-wavelength near-infrared Lasers
    • 6.5.3. Photodynamic Therapy
  • 6.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By Disease Indication, 2023 - 2030
    • 6.6.1. Distal Subungual Onychomycosis
    • 6.6.2. White Superficial Onychomycosis
    • 6.6.3. Proximal Subungual Onychomycosis
    • 6.6.4. Candidal Onychomycosis
    • 6.6.5. Total Dystrophic Onychomycosis
  • 6.7. Current Market Size (US$ Mn) and Volume (Units) Forecast By Age Group, 2023 - 2030
    • 6.7.1. 0 to 18 Years
    • 6.7.2. 18 to 39 Years
    • 6.7.3. 40 to 64 Years
    • 6.7.4. 65 Years & Above
  • 6.8. Current Market Size (US$ Mn) and Volume (Units) Forecast By Distribution Channel, 2023 - 2030
    • 6.8.1. Institutional Sales
    • 6.8.2. Hospitals
    • 6.8.3. Dermatology Clinics
    • 6.8.4. Retail Sales
    • 6.8.5. Retail Pharmacies
    • 6.8.6. Drug Stores
    • 6.8.7. Mail Order Pharmacies & Online Sales
  • 6.9. Market Attractiveness Analysis

7. East Asia Onychomycosis Treatment Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)

  • 7.1. Key Highlights
  • 7.2. Pricing Analysis
  • 7.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
    • 7.3.1. By Country
    • 7.3.2. By Treatment Type
    • 7.3.3. By Disease Indication
    • 7.3.4. By Age Group
    • 7.3.5. By Distribution Channel
  • 7.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
    • 7.4.1. China
    • 7.4.2. Japan
    • 7.4.3. South Korea
  • 7.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Treatment Type, 2023 - 2030
    • 7.5.1. Drugs
      • 7.5.1.1. Oral
      • 7.5.1.2. Rx
      • 7.5.1.3. OTC
      • 7.5.1.4. Topical
      • 7.5.1.5. Rx
      • 7.5.1.6. OTC
    • 7.5.2. Lasers
      • 7.5.2.1. C02 Ablative Lasers
      • 7.5.2.2. Nd: YAG Lasers
      • 7.5.2.3. Dual-wavelength near-infrared Lasers
    • 7.5.3. Photodynamic Therapy
  • 7.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By Disease Indication, 2023 - 2030
    • 7.6.1. Distal Subungual Onychomycosis
    • 7.6.2. White Superficial Onychomycosis
    • 7.6.3. Proximal Subungual Onychomycosis
    • 7.6.4. Candidal Onychomycosis
    • 7.6.5. Total Dystrophic Onychomycosis
  • 7.7. Current Market Size (US$ Mn) and Volume (Units) Forecast By Age Group, 2023 - 2030
    • 7.7.1. 0 to 18 Years
    • 7.7.2. 18 to 39 Years
    • 7.7.3. 40 to 64 Years
    • 7.7.4. 65 Years & Above
  • 7.8. Current Market Size (US$ Mn) and Volume (Units) Forecast By Distribution Channel, 2023 - 2030
    • 7.8.1. Institutional Sales
    • 7.8.2. Hospitals
    • 7.8.3. Dermatology Clinics
    • 7.8.4. Retail Sales
    • 7.8.5. Retail Pharmacies
    • 7.8.6. Drug Stores
    • 7.8.7. Mail Order Pharmacies & Online Sales
  • 7.9. Market Attractiveness Analysis

8. South Asia & Oceania Onychomycosis Treatment Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)

  • 8.1. Key Highlights
  • 8.2. Pricing Analysis
  • 8.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
    • 8.3.1. By Country
    • 8.3.2. By Treatment Type
    • 8.3.3. By Disease Indication
    • 8.3.4. By Age Group
    • 8.3.5. By Distribution Channel
  • 8.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
    • 8.4.1. India
    • 8.4.2. Southeast Asia
    • 8.4.3. ANZ
    • 8.4.4. Rest of South Asia & Oceania
  • 8.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Treatment Type, 2023 - 2030
    • 8.5.1. Drugs
      • 8.5.1.1. Oral
      • 8.5.1.2. Rx
      • 8.5.1.3. OTC
      • 8.5.1.4. Topical
      • 8.5.1.5. Rx
      • 8.5.1.6. OTC
    • 8.5.2. Lasers
      • 8.5.2.1. C02 Ablative Lasers
      • 8.5.2.2. Nd: YAG Lasers
      • 8.5.2.3. Dual-wavelength near-infrared Lasers
    • 8.5.3. Photodynamic Therapy
  • 8.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By Disease Indication, 2023 - 2030
    • 8.6.1. Distal Subungual Onychomycosis
    • 8.6.2. White Superficial Onychomycosis
    • 8.6.3. Proximal Subungual Onychomycosis
    • 8.6.4. Candidal Onychomycosis
    • 8.6.5. Total Dystrophic Onychomycosis
  • 8.7. Current Market Size (US$ Mn) and Volume (Units) Forecast By Age Group, 2023 - 2030
    • 8.7.1. 0 to 18 Years
    • 8.7.2. 18 to 39 Years
    • 8.7.3. 40 to 64 Years
    • 8.7.4. 65 Years & Above
  • 8.8. Current Market Size (US$ Mn) and Volume (Units) Forecast By Distribution Channel, 2023 - 2030
    • 8.8.1. Institutional Sales
    • 8.8.2. Hospitals
    • 8.8.3. Dermatology Clinics
    • 8.8.4. Retail Sales
    • 8.8.5. Retail Pharmacies
    • 8.8.6. Drug Stores
    • 8.8.7. Mail Order Pharmacies & Online Sales
  • 8.9. Market Attractiveness Analysis

9. Latin America Onychomycosis Treatment Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)

  • 9.1. Key Highlights
  • 9.2. Pricing Analysis
  • 9.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
    • 9.3.1. By Country
    • 9.3.2. By Treatment Type
    • 9.3.3. By Disease Indication
    • 9.3.4. By Age Group
    • 9.3.5. By Distribution Channel
  • 9.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
    • 9.4.1. Brazil
    • 9.4.2. Mexico
    • 9.4.3. Rest of Latin America
  • 9.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Treatment Type, 2023 - 2030
    • 9.5.1. Drugs
      • 9.5.1.1. Oral
      • 9.5.1.2. Rx
      • 9.5.1.3. OTC
      • 9.5.1.4. Topical
      • 9.5.1.5. Rx
      • 9.5.1.6. OTC
    • 9.5.2. Lasers
      • 9.5.2.1. C02 Ablative Lasers
      • 9.5.2.2. Nd: YAG Lasers
      • 9.5.2.3. Dual-wavelength near-infrared Lasers
    • 9.5.3. Photodynamic Therapy
  • 9.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By Disease Indication, 2023 - 2030
    • 9.6.1. Distal Subungual Onychomycosis
    • 9.6.2. White Superficial Onychomycosis
    • 9.6.3. Proximal Subungual Onychomycosis
    • 9.6.4. Candidal Onychomycosis
    • 9.6.5. Total Dystrophic Onychomycosis
  • 9.7. Current Market Size (US$ Mn) and Volume (Units) Forecast By Age Group, 2023 - 2030
    • 9.7.1. 0 to 18 Years
    • 9.7.2. 18 to 39 Years
    • 9.7.3. 40 to 64 Years
    • 9.7.4. 65 Years & Above
  • 9.8. Current Market Size (US$ Mn) and Volume (Units) Forecast By Distribution Channel, 2023 - 2030
    • 9.8.1. Institutional Sales
    • 9.8.2. Hospitals
    • 9.8.3. Dermatology Clinics
    • 9.8.4. Retail Sales
    • 9.8.5. Retail Pharmacies
    • 9.8.6. Drug Stores
    • 9.8.7. Mail Order Pharmacies & Online Sales
  • 9.9. Market Attractiveness Analysis

10. Middle East & Africa Onychomycosis Treatment Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)

  • 10.1. Key Highlights
  • 10.2. Pricing Analysis
  • 10.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
    • 10.3.1. By Country
    • 10.3.2. By Treatment Type
    • 10.3.3. By Disease Indication
    • 10.3.4. By Age Group
    • 10.3.5. By Distribution Channel
  • 10.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
    • 10.4.1. GCC
    • 10.4.2. Egypt
    • 10.4.3. South Africa
    • 10.4.4. Northern Africa
    • 10.4.5. Rest of Middle East & Africa
  • 10.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Treatment Type, 2023 - 2030
    • 10.5.1. Drugs
      • 10.5.1.1. Oral
      • 10.5.1.2. Rx
      • 10.5.1.3. OTC
      • 10.5.1.4. Topical
      • 10.5.1.5. Rx
      • 10.5.1.6. OTC
    • 10.5.2. Lasers
      • 10.5.2.1. C02 Ablative Lasers
      • 10.5.2.2. Nd: YAG Lasers
      • 10.5.2.3. Dual-wavelength near-infrared Lasers
    • 10.5.3. Photodynamic Therapy
  • 10.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By Disease Indication, 2023 - 2030
    • 10.6.1. Distal Subungual Onychomycosis
    • 10.6.2. White Superficial Onychomycosis
    • 10.6.3. Proximal Subungual Onychomycosis
    • 10.6.4. Candidal Onychomycosis
    • 10.6.5. Total Dystrophic Onychomycosis
  • 10.7. Current Market Size (US$ Mn) and Volume (Units) Forecast By Age Group, 2023 - 2030
    • 10.7.1. 0 to 18 Years
    • 10.7.2. 18 to 39 Years
    • 10.7.3. 40 to 64 Years
    • 10.7.4. 65 Years & Above
  • 10.8. Current Market Size (US$ Mn) and Volume (Units) Forecast By Distribution Channel, 2023 - 2030
    • 10.8.1. Institutional Sales
    • 10.8.2. Hospitals
    • 10.8.3. Dermatology Clinics
    • 10.8.4. Retail Sales
    • 10.8.5. Retail Pharmacies
    • 10.8.6. Drug Stores
    • 10.8.7. Mail Order Pharmacies & Online Sales
  • 10.9. Market Attractiveness Analysis

11. Competition Landscape

  • 11.1. Market Share Analysis, 2022
  • 11.2. Market Structure
    • 11.2.1. Competition Intensity Mapping By Market
    • 11.2.2. Competition C02 Ablative Lasers
    • 11.2.3. Apparent Product Capacity
  • 11.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
    • 11.3.1. Teva Pharmaceutical Industries Ltd.
      • 11.3.1.1. Overview
      • 11.3.1.2. Segments and Product
      • 11.3.1.3. Key Financials
      • 11.3.1.4. Market Developments
      • 11.3.1.5. Market Strategy
    • 11.3.2. Sanofi S.A.
      • 11.3.2.1. Overview
      • 11.3.2.2. Segments and Product
      • 11.3.2.3. Key Financials
      • 11.3.2.4. Market Developments
      • 11.3.2.5. Market Strategy
    • 11.3.3. Medimetriks Pharmaceuticals, Inc.
      • 11.3.3.1. Overview
      • 11.3.3.2. Segments and Product
      • 11.3.3.3. Key Financials
      • 11.3.3.4. Market Developments
      • 11.3.3.5. Market Strategy
    • 11.3.4. Galderma
      • 11.3.4.1. Overview
      • 11.3.4.2. Segments and Product
      • 11.3.4.3. Key Financials
      • 11.3.4.4. Market Developments
      • 11.3.4.5. Market Strategy
    • 11.3.5. Johnson & Johnson
      • 11.3.5.1. Overview
      • 11.3.5.2. Segments and Product
      • 11.3.5.3. Key Financials
      • 11.3.5.4. Market Developments
      • 11.3.5.5. Market Strategy
    • 11.3.6. Novartis AG
      • 11.3.6.1. Overview
      • 11.3.6.2. Segments and Product
      • 11.3.6.3. Key Financials
      • 11.3.6.4. Market Developments
      • 11.3.6.5. Market Strategy
    • 11.3.7. Moberg Pharma AB
      • 11.3.7.1. Overview
      • 11.3.7.2. Segments and Product
      • 11.3.7.3. Key Financials
      • 11.3.7.4. Market Developments
      • 11.3.7.5. Market Strategy
    • 11.3.8. Cardinal Health, Inc.
      • 11.3.8.1. Overview
      • 11.3.8.2. Segments and Product
      • 11.3.8.3. Key Financials
      • 11.3.8.4. Market Developments
      • 11.3.8.5. Market Strategy
    • 11.3.9. Pfizer Inc.
      • 11.3.9.1. Overview
      • 11.3.9.2. Segments and Product
      • 11.3.9.3. Key Financials
      • 11.3.9.4. Market Developments
      • 11.3.9.5. Market Strategy
    • 11.3.10. Almirall, S.A.
      • 11.3.10.1. Overview
      • 11.3.10.2. Segments and Product
      • 11.3.10.3. Key Financials
      • 11.3.10.4. Market Developments
      • 11.3.10.5. Market Strategy
    • 11.3.11. Bayer AG
      • 11.3.11.1. Overview
      • 11.3.11.2. Segments and Product
      • 11.3.11.3. Key Financials
      • 11.3.11.4. Market Developments
      • 11.3.11.5. Market Strategy
    • 11.3.12. Viatris Inc.
      • 11.3.12.1. Overview
      • 11.3.12.2. Segments and Product
      • 11.3.12.3. Key Financials
      • 11.3.12.4. Market Developments
      • 11.3.12.5. Market Strategy
    • 11.3.13. GlaxoSmithKline plc
      • 11.3.13.1. Overview
      • 11.3.13.2. Segments and Product
      • 11.3.13.3. Key Financials
      • 11.3.13.4. Market Developments
      • 11.3.13.5. Market Strategy
    • 11.3.14. Cipla Ltd.
      • 11.3.14.1. Overview
      • 11.3.14.2. Segments and Product
      • 11.3.14.3. Key Financials
      • 11.3.14.4. Market Developments
      • 11.3.14.5. Market Strategy
    • 11.3.15. Dr. Reddy's Laboratories Ltd
      • 11.3.15.1. Overview
      • 11.3.15.2. Segments and Product
      • 11.3.15.3. Key Financials
      • 11.3.15.4. Market Developments
      • 11.3.15.5. Market Strategy

12. Appendix

  • 12.1. Research Methodology
  • 12.2. Research Assumptions
  • 12.3. Acronyms and Abbreviations